News & Press.
Learn the Latest Elutia Updates
Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance
SILVER SPRING, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a company pioneering drug-eluting biomatrix products, today provided a business update and financial results for the first quarter ended...
Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
SILVER SPRING, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its first quarter 2024 financial results after market close on...
Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1
SILVER SPRING, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson,...
Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024
SILVER SPRING, Md., March 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023. Business...
Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024
SILVER SPRING, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its fourth quarter and full year 2023 financial results after...